217 related articles for article (PubMed ID: 27937095)
21. A Randomized Controlled Trial Using Automated Technology for Improving Ototoxicity Monitoring in VA Oncology Patients.
Konrad-Martin D; O'Connell Bennett K; Garinis A; McMillan GP
Am J Audiol; 2021 Oct; 30(3S):870-886. PubMed ID: 34582263
[TBL] [Abstract][Full Text] [Related]
22. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
23. Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients.
Eiamprapai P; Yamamoto N; Hiraumi H; Ogino-Nishimura E; Kitamura M; Hirano S; Ito J
Laryngoscope; 2012 Jun; 122(6):1392-6. PubMed ID: 22555987
[TBL] [Abstract][Full Text] [Related]
24. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
Knight KR; Kraemer DF; Neuwelt EA
J Clin Oncol; 2005 Dec; 23(34):8588-96. PubMed ID: 16314621
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting.
Paken J; Govender CD; Pillay M; Sewram V
BMC Health Serv Res; 2022 Jun; 22(1):791. PubMed ID: 35717191
[TBL] [Abstract][Full Text] [Related]
26. A Store-and-Forward Tele-Audiology Solution to Promote Efficient Screenings for Ototoxicity during Cisplatin Cancer Treatment.
Dille MF; McMillan GP; Helt WJ; Konrad-Martin D; Jacobs P
J Am Acad Audiol; 2015 Oct; 26(9):750-60. PubMed ID: 26415968
[TBL] [Abstract][Full Text] [Related]
27. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
28. Audiological Monitoring in Children Treated with Platinum Chemotherapy.
Fetoni AR; Ruggiero A; Lucidi D; De Corso E; Sergi B; Conti G; Paludetti G
Audiol Neurootol; 2016; 21(4):203-211. PubMed ID: 27286730
[TBL] [Abstract][Full Text] [Related]
29. Ototoxicity of preradiation cisplatin for children with central nervous system tumors.
Kretschmar CS; Warren MP; Lavally BL; Dyer S; Tarbell NJ
J Clin Oncol; 1990 Jul; 8(7):1191-8. PubMed ID: 2358836
[TBL] [Abstract][Full Text] [Related]
30. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin.
Sriyapai T; Thongyai K; Phuakpet K; Vathana N; Buaboonnam J; Sanpakit K
Turk J Pediatr; 2022; 64(3):531-541. PubMed ID: 35899566
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
[TBL] [Abstract][Full Text] [Related]
32. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
33. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
34. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD010885. PubMed ID: 29975402
[TBL] [Abstract][Full Text] [Related]
35. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; (8):CD010885. PubMed ID: 27498707
[TBL] [Abstract][Full Text] [Related]
36. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
37. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.
Brock PR; Knight KR; Freyer DR; Campbell KC; Steyger PS; Blakley BW; Rassekh SR; Chang KW; Fligor BJ; Rajput K; Sullivan M; Neuwelt EA
J Clin Oncol; 2012 Jul; 30(19):2408-17. PubMed ID: 22547603
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.
Konrad-Martin D; James KE; Gordon JS; Reavis KM; Phillips DS; Bratt GW; Fausti SA
J Am Acad Audiol; 2010 May; 21(5):301-14; quiz 357. PubMed ID: 20569665
[TBL] [Abstract][Full Text] [Related]
39. A new grading system for ototoxicity in adults.
Theunissen EA; Dreschler WA; Latenstein MN; Rasch CR; van der Baan S; de Boer JP; Balm AJ; Zuur CL
Ann Otol Rhinol Laryngol; 2014 Oct; 123(10):711-8. PubMed ID: 24820112
[TBL] [Abstract][Full Text] [Related]
40. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD010885. PubMed ID: 31961948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
